Leap Therapeutics Inc (LPTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Leap Therapeutics Inc (LPTX) has a cash flow conversion efficiency ratio of -6.045x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.29 Million) by net assets ($2.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Leap Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Leap Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Leap Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Leap Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Leap Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INNATE PHARMA SP.ADR/1
F:IDDA
|
N/A |
|
Rajthanee Hospital Public Company Limited
BK:RJH
|
0.088x |
|
PT DFI Retail Nusantara Tbk
JK:HERO
|
0.026x |
|
Renaissance Global Limited
NSE:RGL
|
-0.056x |
|
Studentbostader I Sverige AB
ST:STUDBO
|
0.013x |
|
Falco Resources Ltd
V:FPC
|
-0.005x |
|
Plotech Co Ltd
TW:6141
|
-0.237x |
|
JOYCITY Corporation
KQ:067000
|
0.035x |
Annual Cash Flow Conversion Efficiency for Leap Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Leap Therapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see LPTX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.05 Million | $-60.30 Million | -1.720x | -136.49% |
| 2023-12-31 | $60.14 Million | $-43.75 Million | -0.728x | +18.95% |
| 2022-12-31 | $54.64 Million | $-49.04 Million | -0.898x | -175.43% |
| 2021-12-31 | $107.89 Million | $-35.16 Million | -0.326x | +15.38% |
| 2020-12-31 | $67.41 Million | $-25.96 Million | -0.385x | -102.50% |
| 2019-12-31 | $-1.75 Million | $-26.90 Million | 15.381x | +642.10% |
| 2018-12-31 | $9.18 Million | $-26.03 Million | -2.837x | -42.49% |
| 2017-12-31 | $11.12 Million | $-22.14 Million | -1.991x | -- |
| 2016-12-31 | $0.00 | $-25.34 Million | x | -- |
| 2015-12-31 | $26.87 Million | $-19.58 Million | -0.729x | -86.90% |
| 2014-12-31 | $46.21 Million | $-18.02 Million | -0.390x | +26.38% |
| 2013-12-31 | $18.77 Million | $-9.94 Million | -0.530x | +8.14% |
| 2012-12-31 | $13.10 Million | $-7.55 Million | -0.577x | -- |
About Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more